GEn1E Lifesciences Adds to Development Pipeline with Exclusive Option to License University of Maryland, Baltimore’s MUC1-Ecto-Domain Anti-Bacterial Agent

Press Release

Provides GEn1E the potential to enter clinic with a therapy for Pseudomonas infections in Cystic Fibrosis patients

PALO ALTO, CA, Nov. 19, 2018 (GLOBE NEWSWIRE) -- GEn1E Lifesciences Inc. (“GEn1E”), a pre-clinical stage biopharmaceutical company focused on transforming promising research into therapies for areas of huge unmet medical needs, announced today that it has entered into an exclusive option agreement with the University of Maryland, Baltimore (UMB) to license patent rights entitled “MUC1 Decoy Peptides for Treatment and Prevention of Bacterial Infections,” invented by Erik P. Lillehoj, Ph.D., Avelino C. Verceles, M.D. and Simeon E. Goldblum, M.D., all faculty members of the University of Maryland School of Medicine. 

“The inventors' novel use of MUC1-ED, a natural peptide with anti-bacterial properties for the treatment of Pseudomonas infections, is a compelling complement to antibiotic-based therapies,” said Ritu Lal, Ph.D., GEn1E's co-founder and Chief Executive Officer. “MUC1-ED’s mechanism of action differs from traditional antibiotic therapies and could be used to reduce the bacterial load, slow the development of resistance and shorten the duration of treatment.” 

“The University’s newly formed partnership with GEn1E Lifesciences is very encouraging, and we hope to see it lead to rapid external validation of the MUC1-ED technology,” said Nancy Cowger, Director of Licensing and Alliances for UM Ventures. “It’s also an example of how early-stage technology investment by the University and the state of Maryland – via support from UMB’s Institute for Clinical and Translational Research and the Maryland Innovation Initiative – can enhance the commercial viability of important new medical innovations emerging from academic research.”

"We are excited to enter into this exclusive agreement with UMB and to collaborate with Drs. Lillehoj and Goldblum to further establish the anti-bacterial properties of this peptide. We seek to determine its potential to treat Pseudomonas infections in areas of high need, including individuals with Cystic Fibrosis,” said Dr. Lal. “This collaboration is a welcome opportunity to expand GEn1E’s pipeline of assets and our collaboration with UMB.”

About GEn1E Lifesciences 

GEn1E Lifesciences Inc. is a pre-clinical stage biopharmaceutical company focused on transforming promising research into therapies for areas of huge unmet medical needs. In addition to rights associated with the exclusive option agreement with UMB for its MUC1-ED peptide, GEn1E has an exclusive option with UMB for its p38aKinase inhibitor for treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome and various inflammatory and age-related diseases. 

About the University of Maryland, Baltimore

The University of Maryland, Baltimore is commercializing breakthrough therapies, diagnostics and devices, fueling the creation of innovative start-up companies, and attracting industry leaders and entrepreneurs to its thriving campus. Founded in 1807 as the first public medical school in the nation, the University is a fast-growing biomedical research center with nationally ranked professional schools of dentistry, law, medicine, nursing, pharmacy, social work, an interdisciplinary graduate school as well as a 12 acre biomedical research park. www.umaryland.edu

GEn1E Lifesciences Inc.
info@gen1elifesci.com

www.gen1elifesci.com

GEn1E Lifesciences Granted Exclusive Option to License University of Maryland, Baltimore’s Selective P38 Kinase Inhibitor

Access to University of Maryland, Baltimore’s broadly applicable P38 Kinase inhibitor technology offers GEn1E the potential to enter the clinic with an acute lung injury/acute respiratory distress syndrome therapy

PALO ALTO, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- GEn1E Lifesciences Inc. (“GEn1E”), a pre-clinical stage biopharmaceutical company focused on transforming promising research into therapies for areas of huge unmet medical needs, announced today that it has entered into an exclusive option agreement with the University of Maryland, Baltimore (UMB) to license a patent application entitled "Non-Catalytic Substrate-Selective p38a-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity, and Methods of Use Thereof" invented by Paul S. Shapiro, Ph.D. and Alexander D. MacKerell Jr., Ph.D. of the University of Maryland School of Pharmacy, and Jeffrey D. Hasday, M.D. of the University of Maryland School of Medicine.

The invention is targeted at the treatment of acute lung injury/acute respiratory distress syndrome (“ALI/ARDS”).  Ritu Lal, Ph.D., M.S. (Management), GEn1E's co-founder and Chief Executive Officer, said, “UMB scientists have developed impressive preclinical data in ALI/ARDS animal models, suggesting real potential as a first indication for this invention to help treat patients with ALI/ARDS. This is a rare disease with no therapies approved by the U.S. Food and Drug Administration (FDA). ALI/ARDS has a very high mortality rate (40%) and high hospital/ICU costs in hundreds of thousands of dollars per patient.”

“UMB had identified this technology as having great commercial potential and had Life Science IP funding towards the project,” said Phil Robilotto, Chief Commercialization Officer for UM Ventures. “We are therefore particularly excited to see such a rapid external validation through this exciting strategic partnership with GEn1E Lifesciences.” In addition to UM Ventures funding, this project received support from UMB’s Institute for Clinical and Translational Research. 

“The University of Maryland, Baltimore’s new generation of selective P38 Kinase inhibitors demonstrate impressive efficacy potentially without the toxicities associated with previous generations of non-selective molecules. This creates the potential for a broad platform of applications in aging and inflammatory diseases”, observed Dr. Lal. She concluded, “We are thrilled to begin work with Dr. Shapiro and Dr. Hasday to bring their invention to the clinic, regulatory approval and commercialization to help treat patients in need.”

About GEn1E Lifesciences 
GEn1E Lifesciences Inc. is a pre-clinical stage biopharmaceutical company focused on transforming promising research into therapies for areas of huge unmet medical needs. www.gen1elifesci.com

About the University of Maryland, Baltimore
The University of Maryland, Baltimore is commercializing breakthrough therapies, diagnostics and devices, fueling the creation of innovative start-up companies, and attracting industry leaders and entrepreneurs to its thriving campus. Founded in 1807 as the first public medical school in the nation, the University is a fast-growing biomedical research center with nationally ranked professional schools of dentistry, law, medicine, nursing, pharmacy, social work, an interdisciplinary graduate school as well as a 1.8 million square foot bio-medical research park. www.umaryland.edu

GEn1E Lifesciences Inc.
www.gen1elifesci.com